anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A dental impression composition comprises a gel-forming component consisting of sodium, potassium or ammonium carboxymethyl cellulose, a metal salt component reactive with the gel-forming component in solution to form an elastic gel and an alkali metal fluoride operable to form a hard and smooth surface. The metal salts may be hydrated calcium sulphate, lead monosilicate, lead disilicate, basic lead sulphate, basic lead carbonate, barium sulphate, zinc silicate, zirconium silicate, and salts of strontium.  Retarders such as sodium carbonate, trisodium polyphosphate, sodium meta-, orthoand pyro-phosphate and alkali metal salts of substituted acids of ethylene diamine, and fillers such as powdered talc, clay, diatomaceous earth, calcium carbonate and silica, may also be added. Specification 518,596, [Group V], is referred to.ALSO:A dental impression composition comprises a gelforming component of the group consisting of a water soluble alginate, a gellable pectin material, and a water soluble alkali metal or ammonium carboxy methyl cellulose, a metal salt component reactive with the gel-forming component in solution to form an elastic gel, and an alkali metal fluoride operable to form a hard and smooth surface.  The gel-forming agent may be sodium, potassium, or ammonium alginate, alkali metal pectins or pectates, or sodium, potassium, or ammonium carboxy methyl cellulose.  The metal salts may be hydrated calcium sulphate, lead monosilicate, lead disilicate, basic lead sulphate, basic lead carbonate, barium sulphate, zinc silicate, zirconium silicate, and salts of strontium.  Retarders such as sodium carbonate, trisodium phosphate and polyphosphate, sodium meta-, ortho-, and pyro-phosphate, and alkali metal salts of substituted acids of ethylene diamine, and fillers such as powdered talc, clay, diatomaceous earth, calcium carbonate and silica may also be added. In examples, the composition consists of diatomaceous earth, potassium alginate, lead monosilicate, hydrocal or calcium sulphate hemi hydrate, tetrasodium pyrophosphate, and potassium or sodium fluoride.  Specification 518,596 is referred to.
The objective of this article is to compare the amount of intraoperative blood loss during laparoscopic myomectomy when performing bilateral transient clamping of the uterine and utero-ovarian arteries versus no intervention. It´s a randomized controlled prospective study carried out in the Department of Obstetrics and Gynecology Ramón y Cajal University Hospital and HM Montepríncipe-Sanchinarro University Hospital, Madrid, Spain, in women with fibroid uterus undergoing laparoscopic myomectomy. Eighty women diagnosed with symptomatic fibroid uterus were randomly assigned to undergo laparoscopic myomectomy without additional intervention (Group A) or temporary clamping of bilateral uterine and utero-ovarian arteries prior to laparoscopic myomectomy (Group B). Estimated blood loss, operating time, length of hospital stay, and postoperative hemoglobin values were compared in both groups. The number of fibroids removed was similar in both groups (p = 0.77). Estimated blood loss was lower in the group of patients with prior occlusion of uterine arteries (p = 0.025) without increasing operating time (p = 0.17) nor length of stay (p = 0.17). No patient had either intra or postoperative complications. Only two patients (2.5%) required blood transfusion after surgery. We conclude that temporary clamping of bilateral uterine arteries prior to laparoscopic myomectomy is a safe intervention that reduces blood loss without increasing operative time.
The FIRE intervention was included the progressive balance training, ankle and hip strengthening, range of motion exercises and foot massage. Plantar massage consisted of two, 1-min plantar massages with a 1-min rest between sets. Four previously established exercises were target the IFMs including the short-foot, toe-spread-out, hallux extension, and lesser-toe extension.
OBJECTIVE: The present study aims to investigate the potential impact of celiac disease (CD) on hearing functions and assess the effect of a gluten-free diet (GFD) on this condition.
MATERIALS AND METHODS: The study included 55 children with CD (110 ears) and 25 healthy controls (50 ears) matched for age and gender. The CD group was divided into adherent (n = 31) and nonadherent (n = 24) to GFD. Participants underwent tympanometry and pure tone audiometry assessments covering frequencies from 500 to 4000 Hz.
RESULTS: Patients with CD showed significantly higher air and bone conduction hearing averages compared to the control group at frequencies of 500, 1000, 2000, and 4000 Hz for air conduction, and at 500 Hz for bone conduction (P < 0.05). Celiac patients, those who fully adhered to GFD, had notably higher air conduction hearing averages at 500, 2000, and 4000 Hz compared to healthy controls (P < 0.05). However, there was no difference in bone conduction hearing averages between the two groups. In contrast, celiac patients who did not comply with GFD had statistically significantly higher air and bone conduction hearing averages than the control group (P < 0.05), at frequencies of 500, 1000, and 4000 Hz for air conduction, and at 500 and 1000 Hz for bone conduction (P < 0.05).
CONCLUSIONS: The study suggests that nonadherence to GFD may elevate the risk of hearing loss in children with CD. As a result, it is recommended to conduct hearing screenings for children with CD and underscore the importance of complying with GFD to mitigate further detrimental effects on hearing functions.
DOSAGE MUST BE INDIVIDUALIZED AND CLOSELY MONITORED BY A PHYSICIAN DURING UP-TITRATION. Prior to initiation of carvedilol phosphate extended-release capsules, it is recommended that fluid retention be minimized. The recommended starting dose of carvedilol phosphate extended-release capsules is 10 mg once daily for 2 weeks. Patients who tolerate a dose of 10 mg once daily may have their dose increased to 20, 40, and 80 mg over successive intervals of at least 2 weeks. Patients should be maintained on lower doses if higher doses are not tolerated.

Patients should be advised that initiation of treatment and (to a lesser extent) dosage increases may be associated with transient symptoms of dizziness or lightheadedness (and rarely syncope) within the first hour after dosing. Thus, during these periods, they should avoid situations such as driving or hazardous tasks, where symptoms could result in injury. Vasodilatory symptoms often do not require treatment, but it may be useful to separate the time of dosing of carvedilol phosphate extended-release capsules from that of the ACE inhibitor or to reduce temporarily the dose of the ACE inhibitor. The dose of carvedilol phosphate extended-release capsules should not be increased until symptoms of worsening heart failure or vasodilation have been stabilized.

Fluid retention (with or without transient worsening heart failure symptoms) should be treated by an increase in the dose of diuretics.

The dose of carvedilol phosphate extended-release capsules should be reduced if patients experience bradycardia (heart rate less than 55 beats per minute).

Episodes of dizziness or fluid retention during initiation of carvedilol phosphate extended-release capsules can generally be managed without discontinuation of treatment and do not preclude subsequent successful titration of, or a favorable response to, carvedilol phosphate extended-release capsules.
Genomic technologies, such as targeted, exome and short-read genome sequencing approaches, have revolutionized the care of patients with rare genetic diseases. However, more than half of patients remain without a diagnosis. Emerging approaches from research-based settings such as long-read genome sequencing and optical genome mapping hold promise for improving the identification of disease-causal genetic variants. In addition, new omic technologies that measure the transcriptome, epigenome, proteome or metabolome are showing great potential for variant interpretation. As genetic testing options rapidly expand, the clinical community needs to be mindful of their individual strengths and limitations, as well as remaining challenges, to select the appropriate diagnostic test, correctly interpret results and drive innovation to address insufficiencies. If used effectively - through truly integrative multi-omics approaches and data sharing - the resulting large quantities of data from these established and emerging technologies will greatly improve the interpretative power of genetic and genomic diagnostics for rare diseases.
No carcinogenicity, mutagenicity, or impairment of fertility studies have been conducted with GLIADEL Wafer. Carcinogenicity, mutagenicity, and impairment of fertility studies have been conducted with carmustine, the active component of GLIADEL Wafer. Carmustine was carcinogenic in rats and mice when delivered by intraperitoneal injection at doses lower than those delivered by GLIADEL Wafer at the recommended dose. There were increases in tumor incidence in all treated animals. Carmustine was mutagenic in vitro (Ames assay, human lymphoblast HGPRT assay) and clastogenic both in vitro (V79 hamster cell micronucleus assay) and in vivo (SCE assay in rodent brain tumors, mouse bone marrow micronucleus assay). 

In male rats carmustine caused testicular degeneration at intraperitoneal doses of 8 mg/kg/week for eight weeks (about 1.3 times the recommended human dose based on body surface area).
BACKGROUND: Gastroesophageal reflux disease (GERD) symptoms frequently recur after cessation of acid blockers. The presence of a hiatal hernia may worsen GERD symptoms and increase the risk of esophageal malignancy. The aim of this study is to clarify the timing and predictors for recurrence of GERD symptoms after cessation of vonoprazan (VPZ) therapy.
METHODS: A retrospective observational study involved 86 patients who underwent cessation of VPZ therapy for symptomatic GERD. Collated data from medical record review included the endoscopic findings and Izumo scale score.
RESULTS: The mean duration of continuous VPZ therapy before cessation was 7.9 months. GERD symptoms requiring the resumption of VPZ therapy recurred in 66 of 86 patients (77%). Kaplan-Meier analysis showed that overall recurrence-free rates at 6 months, one and two years after VPZ cessation were 44%, 32% and 23%, respectively. Alcohol use, the presence of a hiatal hernia and long-term therapy for more than six months were identified as significant positive predictors for symptomatic recurrence. Notably, hiatal hernia had the highest hazard ratio in both univariate and multivariate analyses. The recurrence-free rate in patients with a hiatal hernia was much lower at 6 months than in patients without a hiatal hernia (15% and 51%, respectively p = 0.002). After the symptomatic recurrence, GERD symptoms improved significantly after one-month VPZ therapy.
CONCLUSION: The rate of symptomatic recurrence after VPZ cessation in patients with GERD is considerable. Cessation of acid suppression therapy should be cautious in patients with both a hiatal hernia and GERD.
In response to sensory deprivation, the brain adapts according to contemporary demands to efficiently navigate a modified perceptual environment. This reorganization may result in improved processing of the remaining senses-a phenomenon referred to as compensatory crossmodal plasticity. One approach to explore this neuroplasticity is to consider the macrostructural changes in neural tissue that mirror this functional optimization. The current study is the first of its kind to measure MRI-derived gray matter (GM) volumes of control felines (n=30), while additionally identifying volumetric differences in response to perinatal deafness (30 ototoxically-deafened cats). To accomplish this purpose, regional and morphometric methods were performed in parallel. The regional analysis evaluated volumetric alterations of global GM, as well as the volumes of 146 regions of interest (ROIs) and 12 functional subgroupings of these ROIs. Results revealed whole-brain GM preservation; however, somatosensory and visual cortices exhibited an overall increase in volume. On a smaller scale, this analysis uncovered two auditory ROIs (second auditory cortex, A2, and ventral auditory field, VAF) that decreased in volume alongside two visual regions (anteromedial lateral suprasylvian area, AMLS and splenial visual area, SVA) that increased-all localized within the right hemisphere. Comparatively, the findings of tensor-based morphometry (TBM) generally aligned with those of the ROI-based method, as this voxel-wise approach demonstrated clusters of expansion coincident with visual- and somatosensory-related loci; although, it failed to detect any GM reductions following deafness. As distinct differences were identified in each analysis, the current study highlights the importance of employing multiple methods when exploring MRI volumetry. Overall, this study proposes that volumetric alterations within sensory loci allude to a redistribution of cortical space arising from modified perceptual demands following auditory deprivation.
One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
Supplied as tablets for oral administration containing 1 gram ferric citrate (210 milligrams of ferric iron). Administered orally with meals or snacks.
The invention discloses an acetyl gastrodin compound, and a preparation method, a preparation and application thereof. The acetyl gastrodine compound is a eutectic crystal of a compound shown in a formula (I) and urea, and the structural formula of the compound shown in the formula (I) is as follows: (I) is provided. The preparation method comprises the step of reacting the acegastrodine with the urea in an organic solvent system, wherein the organic solvent is one or more of alcohols, ketones, alkyl nitriles and cyclic ethers. The preparation is prepared by adding pharmaceutically acceptable adjuvants into the acetyl gastrodine compound to obtain powder, granule, tablet, capsule and pill. The application is the application of the acetyl gastrodine compound in preparing the medicine for preventing/treating cardiovascular and cerebrovascular diseases. The cocrystal of gastrodin and urea provided by the invention has high solubility, is beneficial to improving the absorption efficiency of the medicament and improving the bioavailability of the medicament, and has important significance for improving the curative effect and safety of the medicament.
Procedure for the obtaining of pharmaceutical barium sulphate that is particularly used in medicine as a contrast element in the x-ray study. Barcely chloride obtained from the reaction of barita with cloydic acid in water is dissolved, with agitation, up to a concentration 1 molar. The iron impurities are eliminated by adding like oxidizing 0.5 l. Of oxygenated water to 30 per 1000 of this dissolution. Ferric hydroxide prepared by adding sodium hydroxide. The solution with active carbon is treated and filtra. Dilute in hot water until concentration 0.18 molar to 60 degrees. Sodium sulfate is diluted in water, at a temperature of 60 degrees, up to a concentration of 0.18 moles/l. And filter. The two compounds are introduced, with a light excess of sodium sulfate, in a reactor with strong agitation. The reaction product is exposeed to a content of at least 25 per 100 in solids. It washes in water current, it takes to an atomizer and separates the sulfate of barium, that dries in current of hot air. (Machine-translation by Google Translate, not legally binding)
A system for processing cannabinoids and recovering solvent has a vessel for a mixture of cannabinoids and solvent. A pump forms a vacuum in the system to draw the mixture into a first heat exchanger to pre-heat the mixture. A falling film evaporator receives the mixture from the first heat exchanger, and boils the mixture to form a solvent vapor. The falling film evaporator collects the cannabinoids from the mixture as a crude oil. The first heat exchanger receives the solvent vapor. Heat is transferred to incoming mixture of the system, and cools and condenses the solvent vapor to form solvent condensate and vapor. A second heat exchanger receives and further cools the solvent condensate and vapor to form further condensed solvent and some solvent vapor. The pump receives the further condensed solvent and some solvent vapor and increases pressure to form solvent liquid and recovers solvent liquid for reuse.
PURPOSE: To obtain a low allergenic-inducible dairy product consisting of a milk component contg. no high allergenic protection and a low allergenic protein components for addition, having favorable taste and flavor peculiar to milk and similar in appearance to skim milk. CONSTITUTION: This low allergenic-inducible dairy product contains a milk component contg. no high allergenic protein obtd. by filtering a milk component with a filter membrane passing molecules having <=5kDa mol.wt. and a low allergenic protein component for addition selected from among a low allergenic protein, an amino acid, polypeptide having <=1.5kDa mol.wt. and a blend of them.
Acute myocarditis is an acute inflammatory cardiomyopathy associated with cardiac damage triggered by a virus or a pathological immune activation. It may present with a wide range of clinical presentations, ranging from mild symptoms to severe forms like fulminant myocarditis, characterized by hemodynamic compromise and cardiogenic shock. The immune system plays a central role in the pathogenesis of myocarditis. In fact, while its function is primarily protective, aberrant responses can be detrimental. In this context, both innate and adaptive immunity play pivotal roles; notably, the innate system offers a non-specific and immediate defense, while the adaptive provides specialized protection with immunological memory. However, dysregulation in these systems can misidentify cardiac tissue, triggering autoimmune reactions and possibly leading to significant cardiac tissue damage. This review highlights the importance of innate and adaptive immune responses in the progression and treatment of acute myocarditis.
Cervical spinal cord injury is a life-altering injury that results in profound loss of upper limb function. Hand function is essential to basic activities of daily living and consequently has a significant impact on patients' quality of life. Tendon transfers and/or tenodesis have traditionally been used to restore hand function in spinal cord injuries - however, in recent years there is growing interest in the role of nerve transfers as a means of accomplishing this goal. Although preliminary results indicate nerve transfers may be well-suited for patients with spinal cord injury, their long term efficacy has not been demonstrated.

This study seeks to evaluate the efficacy of nerve transfers in restoring hand function in patients with cervical spinal injuries. Eligible patients will receive nerve transfer procedure(s) (e.g. brachialis to anterior interosseous nerve, supinator to posterior interosseous) and will be followed post-operatively to assess for changes in strength, functional independence, and quality of life.
Fibromyalgia (FM) is a widespread musculoskeletal pain syndrome characterized by chronic widespread pain, unrefreshing sleep, physical exhaustion, and cognitive difficulties. It occurs in all populations throughout the world, with prevalence between 2% and 4% in general populations. Definition, pathogenesis, diagnosis, and treatment of FM remain points of contention. There is no specific diagnostic laboratory test or biomarker to support the diagnostic process and the diagnosis is clinical. For this reason, rheumatologists and clinical psychologists are strongly involved in the diagnostic process and might benefit from tools for comprehensive psychosomatic assessment. Also the treatment of FM remains a challenge, because pharmacological interventions don't consider psychological and social problems and non-pharmacological treatments have shown poor efficacy and are often tested via non-rigorous methods. A multidisciplinary approach which include biological aspects and psychological one, under comprehensive psychosomatic principles, seem to be the best choice for FM.

The primary aim of the present study is to evaluate the psychological status of FM subjects, focusing on a psychosomatic assessment and then testing the efficacy of a multidisciplinary psychosomatic intervention based on cognitive restructuring followed by museum therapy vs a control condition followed by museum therapy.
The invention discloses lactobacillus fermentum PV22 with antiviral ability and application thereof. Lactobacillus fermentum PV22 was deposited at the Guangdong province culture Collection of microorganisms (GDMCC) at 12/18 of 2020 with the accession number: no. 59 building No. 5 of the Jie No. 100 of the Jie Zhonglu, Guangdong province, Guangzhou city, the preservation number is: GDMCC No. 61376. The lactobacillus fermentum PV22 can significantly reduce the infectivity of virus, achieve the effect of obviously antagonizing virus in a short time, increase the antiviral effect with the prolonging of action time, and improve the survival rate of infected virus cells after infection. Therefore, the lactobacillus fermentum (L.fermentum) PV22 can be applied to the preparation of products (such as food, medicines, health care products and the like) for preventing or treating virus infection, and has huge application prospect.
BACKGROUND: Despite the increasing recognition of PD-L1 as predictor of immunotherapeutic response in various malignancies, its role and prognostic significance in thyroid cancer remain underexplored and subject to debate. This study begins to address this gap by comprehensively analyzing PD-L1 expression in papillary thyroid carcinoma (PTC) and investigating its correlation with key clinicopathological variables.
METHODS: We conducted immunohistochemistry (IHC) to assess PD-L1 expression in whole-tissue sections from 121 primary papillary thyroid carcinoma (PTC) cases. We then analyzed the correlations between PD-L1 expression and various clinicopathological variables.
RESULTS: PD-L1 expression was detected in 33.1% of papillary thyroid carcinomas (PTCs), predominantly exhibiting weak to moderate intensity. Notably, this study found no significant correlation between PD-L1 expression and various clinicopathological variables. The lack of association with traditional factors such as age, sex, histological subtype, and tumor size suggests the complex and multifaceted nature of PD-L1 regulation in PTC. Multivariate logistic regression analysis identified chronic lymphocytic thyroiditis with oncocytic metaplasia as the sole independent predictor of PD-L1 expression (P = 0.014), underlining the potential influence of the tumor microenvironment on immune checkpoint expression in PTC.
CONCLUSIONS: Our study underscores the intricate interplay between chronic lymphocytic thyroiditis with oncocytic metaplasia and PD-L1 expression in papillary thyroid carcinoma. The observed link suggests a potential avenue for therapeutic intervention using anti-PD-1/PD-L1 therapies in surgery-refractory PTC. Understanding the dynamics of immune checkpoint regulation in the context of the tumor microenvironment is crucial for devising effective treatment strategies. Future research endeavors should delve deeper into the molecular mechanisms underlying this interaction and explore its implications for patient outcomes. As the field of immunotherapy continues to evolve, our findings contribute valuable insights into the complex immunological landscape of thyroid cancer.